These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28387494)

  • 1. [Optimizing basal insulin therapy in type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2017 Mar; 72(3):156-161. PubMed ID: 28387494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic options for a type 2 diabetic patient not well controlled with metformin plus basal insulin].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2017 Aug; 13(571):1416-1420. PubMed ID: 28837278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [How I manage a patient with type 2 diabetes not well controlled with a metformin plus gliptin combination].
    Scheen AJ
    Rev Med Liege; 2019 Sep; 74(9):443-450. PubMed ID: 31486312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [About the choice between a DPP-4 inhibitor and a SGLT 2 inhibitor tor treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2016 Dec; 71(12):579-585. PubMed ID: 28387100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Gliptin-gliflozin combination for treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1407-1417. PubMed ID: 27435042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
    Avogaro A; Delgado E; Lingvay I
    Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rationale supporting basal insulin-incretin combined therapies in type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Liege; 2013 Nov; 68(11):562-8. PubMed ID: 24396969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of 'treatment resistant' type 2 diabetes.
    Scheen AJ
    Expert Opin Pharmacother; 2017 Apr; 18(5):503-515. PubMed ID: 28276972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New forms of insulin and insulin therapies for the treatment of type 2 diabetes.
    Cahn A; Miccoli R; Dardano A; Del Prato S
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):638-52. PubMed ID: 26051044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of Type 2 Diabetes: a Practical Approach].
    Donath M
    Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Use of oral glucose-lowering agents in patients with renal impairment].
    Scheen AJ; Paquot N
    Rev Med Liege; 2017 Oct; 72(10):462-468. PubMed ID: 29058840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of combination therapy with an insulin sensitizer and a DPP-4(dipeptidyl peptidase-4) inhibitor].
    Yasuda T; Shimomura I
    Nihon Rinsho; 2013 Mar; 71(3):555-62. PubMed ID: 23631252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
    Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
    Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How I TREAT ... THE ROLE OF DPP-4 INHIBITORS (GLIPTINS) IN THE TREATMENT OF TYPE 2 DIABETES].
    Scheen AJ
    Rev Med Liege; 2015 Dec; 70(12):593-9. PubMed ID: 26867302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.